More so, the results of the conjoint analysis with imaging told us that both RAI14 and tumor volume had very similar changing trends; besides, the decline rate of RAI14 offered an exact judgment of the efficacy and the results were matched with the clinical results, which further confirmed that RAI14 is a more suitable parameter in cancer monitoring than CA15-3 and CEA, as well as providing a more reliable and precise basis for the determination of chemotherapy effects. The gene discussed is RAI14; the disease is neoplasm.